These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 1660142)

  • 1. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein.
    Scanlon KJ; Jiao L; Funato T; Wang W; Tone T; Rossi JJ; Kashani-Sabet M
    Proc Natl Acad Sci U S A; 1991 Dec; 88(23):10591-5. PubMed ID: 1660142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Circumventing drug resistance in human tumors by antisense ribozyme].
    Funato T
    Gan To Kagaku Ryoho; 1994 Feb; 21(3):336-42. PubMed ID: 8109989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The utility of an anti-fos ribozyme in reversing cisplatin resistance in human carcinomas.
    Funato T; Yoshida E; Jiao L; Tone T; Kashani-Sabet M; Scanlon KJ
    Adv Enzyme Regul; 1992; 32():195-209. PubMed ID: 1496917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribozyme-mediated reversal of the multidrug-resistant phenotype.
    Scanlon KJ; Ishida H; Kashani-Sabet M
    Proc Natl Acad Sci U S A; 1994 Nov; 91(23):11123-7. PubMed ID: 7972021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells.
    Kashani-Sabet M; Wang W; Scanlon KJ
    J Biol Chem; 1990 Jul; 265(19):11285-8. PubMed ID: 2113532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of cisplatin resistance in vivo by an anti-fos ribozyme.
    Funato T; Ishii T; Kanbe M; Scanlon KJ; Sasaki T
    In Vivo; 1997; 11(3):217-20. PubMed ID: 9239514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of a high activity c-erbB-2 ribozyme using a fusion gene of c-erbB-2 and the enhanced green fluorescent protein.
    Wiechen K; Zimmer C; Dietel M
    Cancer Gene Ther; 1998; 5(1):45-51. PubMed ID: 9476966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ribozyme mediated degradation of beta-amyloid peptide precursor mRNA in COS-7 cells.
    Denman RB; Smedman M; Ju W; Rubenstein R; Potempska A; Miller DL
    Nucleic Acids Res; 1994 Jun; 22(12):2375-82. PubMed ID: 8036167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of the malignant phenotype by an anti-ras ribozyme.
    Kashani-Sabet M; Funato T; Tone T; Jiao L; Wang W; Yoshida E; Kashfinn BI; Shitara T; Wu AM; Moreno JG
    Antisense Res Dev; 1992; 2(1):3-15. PubMed ID: 1422085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of hammerhead ribozyme against human thymidylate synthase on the cytotoxicity of thymidylate synthase inhibitors.
    Kobayashi H; Takemura Y; Miyachi H; Skelton L; Jackman AL
    Jpn J Cancer Res; 1995 Nov; 86(11):1014-8. PubMed ID: 8567390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity.
    Taverna P; Hansson J; Scanlon KJ; Hill BT
    Carcinogenesis; 1994 Sep; 15(9):2053-6. PubMed ID: 7923602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribozyme-mediated downregulation of human metallothionein II(a) induces apoptosis in human prostate and ovarian cancer cell lines.
    Tekur S; Ho SM
    Mol Carcinog; 2002 Jan; 33(1):44-55. PubMed ID: 11807957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cleavage of full-length beta APP mRNA by hammerhead ribozymes.
    Denman RB
    Nucleic Acids Res; 1993 Aug; 21(17):4119-25. PubMed ID: 8371986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribozymes designed to inhibit transformation of NIH3T3 cells by the activated c-Ha-ras gene.
    Koizumi M; Kamiya H; Ohtsuka E
    Gene; 1992 Aug; 117(2):179-84. PubMed ID: 1639266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constructing the eukaryotic expression vector to study preliminarily the functions of hammerhead ribozyme targeting base excision repair gene HOGG1.
    Zhang ZZ; Zhang Q; Wu M
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Mar; 37(2):165-70. PubMed ID: 16608066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of c-fms proto-oncogene in an ovarian carcinoma cell line by a hammerhead ribozyme.
    Yokoyama Y; Morishita S; Takahashi Y; Hashimoto M; Tamaya T
    Br J Cancer; 1997; 76(8):977-82. PubMed ID: 9376277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Circumventing multidrug resistance in human cancer by anti-ribozyme].
    Funato T
    Nihon Rinsho; 1997 May; 55(5):1116-21. PubMed ID: 9155162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of antisense and ribozyme accessible sites on native mRNAs: application to NCOA3 mRNA.
    Scherr M; LeBon J; Castanotto D; Cunliffe HE; Meltzer PS; Ganser A; Riggs AD; Rossi JJ
    Mol Ther; 2001 Nov; 4(5):454-60. PubMed ID: 11708882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oligonucleotide scanning of native mRNAs in extracts predicts intracellular ribozyme efficiency: ribozyme-mediated reduction of the murine DNA methyltransferase.
    Scherr M; Reed M; Huang CF; Riggs AD; Rossi JJ
    Mol Ther; 2000 Jul; 2(1):26-38. PubMed ID: 10899825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical and molecular properties of cisplatin-resistant A2780 cells grown in folinic acid.
    Lu Y; Han J; Scanlon KJ
    J Biol Chem; 1988 Apr; 263(10):4891-4. PubMed ID: 3258308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.